82 related articles for article (PubMed ID: 1856575)
21. Apolipoprotein A-IV levels and phenotype distribution in NIDDM.
Vergès BL; Vaillant G; Goux A; Lagrost L; Brun JM; Gambert P
Diabetes Care; 1994 Aug; 17(8):810-7. PubMed ID: 7956623
[TBL] [Abstract][Full Text] [Related]
22. Effects of continuous insulin infusion therapy on lipoprotein surface and core lipid composition in insulin-dependent diabetes mellitus.
Bagdade JD; Helve E; Taskinen MR
Metabolism; 1991 May; 40(5):445-9. PubMed ID: 2023530
[TBL] [Abstract][Full Text] [Related]
23. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
Atmeh RF; Stewart JM; Boag DE; Packard CJ; Lorimer AR; Shepherd J
J Lipid Res; 1983 May; 24(5):588-95. PubMed ID: 6875383
[TBL] [Abstract][Full Text] [Related]
24. Effect of different insulin regimens on plasma lipoprotein and apolipoprotein concentrations in patients with non-insulin-dependent diabetes mellitus.
Lindström T; Arnqvist HJ; Olsson AG
Atherosclerosis; 1990 Mar; 81(2):137-44. PubMed ID: 2182032
[TBL] [Abstract][Full Text] [Related]
25. Abnormal high-density lipoprotein composition in women with insulin-dependent diabetes.
Bagdade JD; Subbaiah PV
J Lab Clin Med; 1989 Feb; 113(2):235-40. PubMed ID: 2915187
[TBL] [Abstract][Full Text] [Related]
26. The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
Cortese C; Marenah CB; Miller NE; Lewis B
Atherosclerosis; 1982 Sep; 44(3):319-25. PubMed ID: 7150396
[TBL] [Abstract][Full Text] [Related]
27. High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.
Saku K; Zhang B; Jimi S; Bai H; Hirata K; Sasaki N; Liu R; Arakawa K
Eur J Clin Pharmacol; 1995; 48(3-4):209-15. PubMed ID: 7589043
[TBL] [Abstract][Full Text] [Related]
28. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
Reaven PD; Parthasarathy S; Beltz WF; Witztum JL
Arterioscler Thromb; 1992 Mar; 12(3):318-24. PubMed ID: 1547191
[TBL] [Abstract][Full Text] [Related]
29. [Lipoprotein (a) and non-insulin dependent diabetes mellitus].
Chi J; Tang W; Sun M
Zhonghua Nei Ke Za Zhi; 1996 Apr; 35(4):246-8. PubMed ID: 9387640
[TBL] [Abstract][Full Text] [Related]
30. Lipid and lipoprotein abnormalities in diabetic patients with peripheral vascular disease.
Laakso M; Pyörälä K
Atherosclerosis; 1988 Nov; 74(1-2):55-63. PubMed ID: 3214481
[TBL] [Abstract][Full Text] [Related]
31. Effect of probucol on hypercholesterolemia in renal transplant patients.
Okubo M; Nakamura M; Horii A; Kamata K; Takeuchi Y; Tsukamoto Y; Kobayashi N; Sato K; Endo T
Kidney Int Suppl; 1999 Jul; 71():S229-30. PubMed ID: 10412784
[TBL] [Abstract][Full Text] [Related]
32. Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice.
Hayek T; Chajek-Shaul T; Walsh A; Azrolan N; Breslow JL
Arterioscler Thromb; 1991; 11(5):1295-302. PubMed ID: 1911715
[TBL] [Abstract][Full Text] [Related]
33. Positive correlation between probucol in low density lipoprotein and LDL-lowering.
Shinomiya M; Shirai K; Saito Y; Yoshida S
Eur J Clin Pharmacol; 1993; 45(4):343-6. PubMed ID: 8299667
[TBL] [Abstract][Full Text] [Related]
34. Marked decrease in serum HDL cholesterol levels by combined probucol-pravastatin treatment in hypercholesterolemic NIDDM patients.
Ikeda T
Diabetes Care; 1993 May; 16(5):849-50. PubMed ID: 8495635
[No Abstract] [Full Text] [Related]
35. [Separation of high density lipoprotein (HDL) using anti-apo A-I, apo A-II immuno-affinity chromatography to evaluate the effects of probucol].
Kagami A; Hino K; Mochizuki K; Sakamoto T; Tada N; Ishikawa T; Manabe M; Satoh N
Nihon Ronen Igakkai Zasshi; 1991 Nov; 28(6):748-54. PubMed ID: 1795436
[TBL] [Abstract][Full Text] [Related]
36. Clinofibrate therapy raises high-density lipoprotein levels and lowers atherogenic index in diabetes mellitus patients.
Okada S; Miyai Y; Ichiki K; Sato K; Masaki Y; Higuchi T; Ogino Y; Ota Z
J Int Med Res; 1989; 17(6):521-5. PubMed ID: 2628128
[TBL] [Abstract][Full Text] [Related]
37. Effects of long-term treatment with probucol on serum lipoproteins in cases of familial hypercholesterolemia in the elderly.
Morisaki N; Mori S; Kobayashi J; Ishikawa Y; Shinomiya M; Shirai K; Saito Y; Yoshida S
J Am Geriatr Soc; 1990 Jan; 38(1):15-8. PubMed ID: 2295765
[TBL] [Abstract][Full Text] [Related]
38. Clinical and therapeutic use of probucol.
Berg A; Baumstark MW; Frey I; Halle M; Keul J
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S81-4. PubMed ID: 2044650
[TBL] [Abstract][Full Text] [Related]
39. Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus.
Schneider J; Erren T; Zöfel P; Kaffarnik H
Atherosclerosis; 1990 May; 82(1-2):97-103. PubMed ID: 2193640
[TBL] [Abstract][Full Text] [Related]
40. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
Johansson J; Olsson AG; Bergstrand L; Elinder LS; Nilsson S; Erikson U; Mölgaard J; Holme I; Walldius G
Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1049-56. PubMed ID: 7627695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
